List of Fosrenol drug patents
Fosrenol is owned by Takeda Pharms Usa.
Fosrenol contains Lanthanum Carbonate.
Fosrenol has a total of 4 drug patents out of which 0 drug patents have expired.
Fosrenol was authorised for market use on 24 September, 2014.
Fosrenol is available in powder;oral dosage forms.
Fosrenol can be used as reduction of serum phosphate in patients with end stage renal disease.
The generics of Fosrenol are possible to be released after 01 December, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 6 months from now) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 6 months from now) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(7 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 24 September, 2014
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER;ORAL
FOSRENOL family patents
14
United States
7
Japan
6
European Union
5
Denmark
4
Australia
4
Poland
4
Spain
4
Cyprus
4
Slovenia
4
Portugal
4
China
4
Canada
3
Korea, Republic of
3
Brazil
3
EA
2
Austria
2
Germany
2
Hungary
2
South Africa
2
Norway
1
Hong Kong
1
Finland
1
Israel
1
Mexico
1
IB
1
Argentina
1
Peru
1
Singapore
1
Iceland
1
New Zealand
1
Czech Republic
1
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic